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Changes in Anticoagulant Utilization Among United States Nursing
Home Residents With Atrial Fibrillation From 2011 to 2016
Matthew Alcusky, PharmD, MS; David D. McManus, MD, ScM; Anne L. Hume, PharmD; Marc Fisher, MD; Jennifer Tjia, MD, MS;
Kate L. Lapane, PhD
Background-—Nursing home residents with atrial ﬁbrillation are at high risk for ischemic stroke and bleeding events. The most
recent national estimate (2004) indicated less than one third of this high-risk population was anticoagulated. Whether direct-acting
oral anticoagulant (DOAC) use has disseminated into nursing homes and increased anticoagulant use is unknown.
Methods and Results-—A repeated cross-sectional design was used to estimate the point prevalence of oral anticoagulant use on
July 1 and December 31 of calendar years 2011 to 2016 among Medicare fee-for-service beneﬁciaries with atrial ﬁbrillation
residing in long-stay nursing homes. Nursing home residence was determined using Minimum Data Set 3.0 records. Medicare Part
D claims for apixaban, dabigatran, edoxaban, rivaroxaban, and warfarin were identiﬁed and point prevalence was estimated by
determining if the supply from the most recent dispensing covered each point prevalence date. A Cochran-Armitage test was
performed for linear trend in prevalence. On December 31, 2011, 42.3% of 33 959 residents (median age: 85; Q1 79, Q3 90) were
treated with an oral anticoagulant, of whom 8.6% used DOACs. The proportion receiving treatment increased to 47.8% of 37 787
residents as of December 31, 2016 (P<0.01); 48.2% of 18 054 treated residents received DOACs. Demographic and clinical
characteristics of residents using DOACs and warfarin were similar in 2016. Half of the 8734 DOAC users received standard
dosages and most were treated with apixaban (54.4%) or rivaroxaban (35.8%) in 2016.
Conclusions-—Increases in anticoagulant use among US nursing home residents with atrial ﬁbrillation coincided with declining
warfarin use and increasing DOAC use. ( J Am Heart Assoc. 2019;8:e012023. DOI: 10.1161/JAHA.119.012023.)
Key Words: anticoagulant • atrial ﬁbrillation • nursing home • utilization
T he number of Americans with atrial ﬁbrillation (AF) isprojected to double to >12 million between 2010 and
2050, driven by increasing population size, aging, and a rising
burden of risk factors such as obesity.1 By 2050, more than
half of Americans with AF are expected to be aged
>80 years.2 As of 2010, 1 in 8 Americans aged >85 years
resided in an institutional setting.3
Anticoagulation decisions for older adults with AF at high
risk for ischemic stroke are particularly challenging because
most are also at high risk of bleeding. This leaves providers
uncertain of the net beneﬁt of treatment4,5 and has
contributed to low use of anticoagulants for high-risk older
adults6 despite evidence supporting their safety and effec-
tiveness for older populations.7 Nursing home residents with
AF are at particularly high risk for ischemic stroke and
bleeding events because of a high prevalence of risk factors,
including frailty, advanced age, and comorbidities.8–10 Yet in
the ﬁnal wave of the National Nursing Home Study conducted
in 2004, less than one third of this high-risk population was
anticoagulated.10 Historically, nursing home residents com-
monly experienced high rates of adverse events related to
warfarin therapy, many of which were considered preventable
and associated with time spent outside of the therapeutic
range.11
Among patients in the United States attending ambulatory
care visits, the market entrance of direct-acting oral antico-
agulants (DOACs) was followed by a shift in use from warfarin
to DOACs, accompanied by an increase in the fraction of
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patients with AF receiving anticoagulation.12 This shift
extends to high-risk community dwelling older adults, as the
large majority of high-risk patients initiating anticoagulants
during the period 2013 to 2016 were prescribed DOACs.13
Nursing home residents have a high burden of cognitive
impairment and shortened life expectancy,14,15 which
demands a complex multi-stakeholder shared decision-mak-
ing process. Furthermore, extensive functional limitations16
diminish residents’ access to specialists outside of the
institutional setting who have a greater propensity to
prescribe anticoagulants overall and DOACs speciﬁcally.17,18
It is uncertain the extent to which the use of DOACs has
disseminated into the nursing home setting and increased
anticoagulant use for this high-risk and vulnerable population.
Methods
Data
Medicare administrative ﬁles and the Minimum Data Set
(MDS) 3.0 were linked to assemble a near-comprehensive
data source encompassing enrollment and demographic
characteristics from the Medicare Beneﬁciary Summary ﬁle,
hospital and skilled nursing facility claims (Medicare Part A),
prescription claims (Medicare Part D), and clinical and
functional assessment data (MDS 3.0). The MDS 3.0 is
mandatory for all Medicare and Medicaid certiﬁed nursing
facilities and the information collected through the MDS 3.0
has been previously validated.19 Medicare administrative ﬁles
and the MDS 3.0 were used through a data use agreement
with the Centers for Medicare and Medicaid Services. Dr
Alcusky had full access to all study data and takes respon-
sibility for data integrity and analysis. Because of the sensitive
nature of the Centers for Medicare and Medicaid Services
research identiﬁable ﬁles, researchers interested in request-
ing ﬁles should consult the information available from the
Research Data Assistance Center.20 The University of Mas-
sachusetts Medical School Institutional Review Board
approved this study (H00015376); informed consent was
not required.
Study Design
A repeated cross-sectional design was used to estimate the
point prevalence of oral anticoagulant use overall, by antico-
agulant class (ie, warfarin or DOAC), and by speciﬁc
medication on July 1 and December 31 of calendar years
2011 to 2016. A 12-month lookback period was used for all
cross-sections with the exception of the ﬁrst because
Medicare and MDS 3.0 data were only available for 6 and
9 months, respectively, before July 1, 2011.
Study Population
For each cross-section, Medicare fee-for-service beneﬁciaries
with diagnosed AF residing in a long-stay nursing home on the
point prevalence date and with at least 6 months of baseline
Medicare enrollment were eligible to enter the study popu-
lation. Included residents had at least one diagnosis of AF or
ﬂutter (Table S1) on a Medicare Part A claim and one
diagnosis of AF, atrial ﬂutter, or dysrhythmia on an MDS 3.0
assessment in the 12 months preceding the point prevalence
date. Excluded residents were aged <65 years, without at
least one Part D claim in the preceding 12 months, enrolled in
hospice, or in a comatose state.
Anticoagulant Use
Oral anticoagulant use including apixaban, dabigatran, edox-
aban, rivaroxaban, or warfarin was measured using a daily
approach, enabling a precise estimate of current anticoagu-
lant use in a national population of residents who were known
to be residing in a nursing home on a speciﬁc date. The point
prevalence of oral anticoagulant use was estimated on the
ﬁrst day of each half-year of the study (July 1 and December
31 of calendar years 2011–2016) by summing the number of
Clinical Perspective
What Is New?
• From 2011 to 2016, the proportion of the US nursing home
population with atrial ﬁbrillation that was treated with an
oral anticoagulant increased from 42% to 48%.
• In 2016, nearly half of treated residents were using direct-
acting oral anticoagulants and more than half of those using
direct-acting oral anticoagulants were using apixaban.
• In 2016, 44% of direct-acting oral anticoagulant users
without renal impairment received low dosages and 44%
with renal impairment received standard dosages.
What Are the Clinical Implications?
• Despite recent increases in oral anticoagulant use, more
than half of nursing home residents with atrial ﬁbrillation
remain untreated.
• Nursing home residents represent a vulnerable population
for whom decisions to initiate, alter, or discontinue treat-
ment are complicated by several factors including medical
morbidity, cognitive impairment, functional limitations, and
abbreviated life expectancy.
• The large shift from warfarin to direct-acting oral anticoag-
ulants among nursing home residents during the period
2011 to 2016 has occurred without comparative effective-
ness evidence speciﬁc to this population to guide medica-
tion and dosage selection.
DOI: 10.1161/JAHA.119.012023 Journal of the American Heart Association 2
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eligible residents exposed to an anticoagulant on that date
and dividing by the number of residents in the population.
Exposure was estimated using ﬁll dates and number of days
supplied from Part D claims in the 12-months preceding the
point prevalence date. Each day a resident was present in the
study population was marked as exposed if the supply from
the most recent dispensing was sufﬁcient to cover that day,
accounting for medication accumulation and in-patient/
skilled nursing facility stays. Residents with at least one
dispensing for an oral anticoagulant who were not exposed on
the point prevalence date were considered to have discon-
tinued anticoagulant use. For analyses of switching at the
level of the class (warfarin or DOAC), residents that made
multiple switches during a cross-section were grouped
according to the most recent switch. Among switchers, the
proportion switching from one class to the other and back
was also described.
Resident Characteristics
Resident characteristics were operationalized using informa-
tion from the most recent long-stay MDS 3.0 assessment
preceding the point prevalence date, diagnoses on Part A
claims and medication information on Part D claims during the
12-months preceding the point prevalence date. Resident
characteristics included demographics, hospital admissions
(including for ischemic stroke,21 extracranial bleeding,22 or
intracranial hemorrhage22), CHA2DS2-VASc risk score,
23
Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA)
risk score,24 select comorbid conditions associated with
increased ischemic stroke (ie, components of the CHA2ADS2-
Vasc score) or bleeding risk25 (fall history, chronic renal
insufﬁciency26), select medication classes and total unique
medications (as an indicator of polypharmacy) used, func-
tional status, and cognitive impairment. Renal functioning was
grouped in 4 categories using a combination of information
from Medicare claims and MDS 3.0 items: (1) on dialysis
(MDS item O0100J2), (2) end-stage renal disease (MDS item
I1500) and not on dialysis, (3) chronic renal insufﬁciency
(corresponding to an estimated glomerular ﬁltration rate
<60 mL/min)26 without end-stage renal disease or dialysis,
and (4) no evidence of chronic renal impairment. The select
medication classes described were those associated with
increased bleeding risk (non-steroidal anti-inﬂammatory
drugs, antiplatelets) and chronic medications (statins, angio-
tensin-converting enzyme inhibitors, angiotensin-receptor
blockers) used for the prevention of cardiovascular and
cerebrovascular events. Use of selective serotonin reuptake
inhibitors was also described because of a possible associ-
ation with bleeding when combined with anticoagulant
use.27,28 A recent history of ≥1 falls since nursing home
admission or the last assessment was ascertained from the
MDS 3.0 (item J1800) and operationalized dichotomously.
Functional status was operationalized as the 4-item activities
of daily living (ADL) score, which summarizes a resident’s
ability to perform 4 ADLs (personal hygiene, toileting,
locomotion, and eating) and ranges from a score of 0
(independent in all 4 ADLs) to 16 (totally dependent in all 4
ADLs).29 Cognitive impairment was scored using the MDS 3.0
Cognitive Function Scale.14
Statistical Analysis
Characteristics of the study population were described overall
and by anticoagulant use for the residents included in the
December 31, 2011 and 2016 point prevalence estimates.
Among residents using oral anticoagulants as of December
31, 2011 and 2016, resident characteristics were summa-
rized separately for users of DOACs and warfarin. Descriptive
statistics included frequencies and percentages for categor-
ical variables and medians with ﬁrst and third quartiles for
continuous variables.
The prevalence of anticoagulant use was plotted overall
and by anticoagulant class for the 12 half-years comprising
the study period. For each half-year, the prevalence of
anticoagulant use was also described by speciﬁc medication.
The prevalence of anticoagulant use overall and by medication
class was also described within subgroups deﬁned by renal
function, cognition, and functional status for the December
31, 2011 and 2016 cross-sections. The prevalence of
anticoagulant discontinuation and the prevalence of switching
between medication classes were each plotted over the
course of the study period. A Cochran-Armitage test with a 2-
sided statistical signiﬁcance level of <0.05 was performed for
linear trend in prevalence of anticoagulant use. Data analyses
were performed with SAS Version 9.4 (SAS Institute Inc) and
Microsoft Excel 2016 (Microsoft Corporation).
Results
Resident Characteristics
The number of residents included ranged from 17 895 for the
July 1, 2011 cross-section to 37 787 for the December 31,
2016 cross-section. Resident age remained consistent
between 2011 (median: 85; Q1 79, Q3 90) and 2016
(median: 84; Q1 78, Q3 90). In 2016, 34% of residents were
men; with 29% men in 2011. The proportion of residents with
CHA2DS2-Vasc scores ≥6 was 36% in 2011 and 30% in 2016;
in each time period >99% of residents had scores of ≥2. The
fraction with renal impairment (chronic renal insufﬁciency,
end-stage renal disease, or using dialysis) was 51% in 2016
and 43% in 2011. Residents were substantially limited in ADLs
in 2011 and 2016. The prevalence of moderate-to-severe
DOI: 10.1161/JAHA.119.012023 Journal of the American Heart Association 3
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cognitive impairment was 39% in 2011 and 34% in 2016. The
median number of unique prescriptions among residents in
2011 was 17 and in 2016 was 18.
Table 1 displays characteristics of the resident population
in 2011 and 2016 for both treated and untreated residents. In
2011 and 2016, the median CHA2DS2-Vasc score was 5 (Q1
4, Q3 6) and the median ATRIA risk score was 3 (Q1 3, Q3 6)
among both treated and untreated residents. In 2011,
moderate-to-severe cognitive impairment was present among
44% of untreated and 34% of treated residents, while in 2016
the prevalence was 40% and 30%, respectively. During the
2011 and 2016 cross-sections, 5% of untreated and 7% of
treated residents had been hospitalized for ischemic stroke.
Among untreated residents, 23% used antiplatelets in 2011
and 19% used antiplatelets in 2016; <10% of treated
residents used antiplatelet medication during either time
period. Table 2 displays characteristics of nursing home
residents treated with DOACs and warfarin in 2011 and
2016.
Table 1. Characteristics of Residents Treated or Not Treated
With an Anticoagulant, by Time Point
December 31, 2011 December 31, 2016
Untreated
(n=19 598)
Treated
(n=14 361)
Untreated
(n=19 733)
Treated
(n=18 054)
Demographics
Age in y,
median
(Q1, Q3)
86 (80, 91) 84 (78, 89) 86 (79, 91) 83 (77, 89)
Women, % 70.9 71.2 66.2 65.9
Hospital admissions in prior year, %
Number of hospitalizations, %
2 to 3 38.0 38.4 36.8 37.9
4+ 13.7 14.1 12.1 13.1
Ischemic
stroke
5.0 7.3 4.7 7.3
Extracranial
bleed
7.9 5.3 7.2 4.5
Intracranial
hemorrhage
1.0 0.4 1.2 0.5
Unique
medications,
median
(Q1, Q3)
17 (12, 22) 19 (14, 24) 16 (12, 22) 18 (14, 24)
Select medications, %*
NSAID 18.3 15.8 17.7 16.9
Antiplatelet 22.5 9.5 18.5 8.6
Statin 42.4 51.0 51.1 60.6
SSRI 52.3 55.9 50.0 52.0
ACE inhibitor
or ARB
49.8 54.0 45.3 50.1
Select comorbidities, %†
Diabetes
mellitus
35.2 41.0 36.3 41.8
Heart failure 42.1 48.7 42.0 48.1
Hypertension 82.7 84.3 85.7 87.8
Coronary
artery
disease
33.4 31.2 31.3 29.3
Anemia 38.4 32.4 39.2 33.2
Fall since
nursing home
admission/
last
assessment
22.1 18.8 21.8 18.1
Stroke 19.6 24.3 12.5 16.2
CHA2DS2-Vasc Risk Score, %
2 to 3 13.6 11.1 15.7 13.0
4 25.0 22.3 26.9 24.3
Continued
Table 1. Continued
December 31, 2011 December 31, 2016
Untreated
(n=19 598)
Treated
(n=14 361)
Untreated
(n=19 733)
Treated
(n=18 054)
5 27.1 27.3 28.1 29.7
6 19.4 21.7 18.7 20.3
7+ 14.5 17.4 10.1 12.4
ATRIA Bleeding Risk Score, %‡
Low (0–3) 54.1 60.8 50.7 55.8
Intermediate
(4)
3.6 4.6 5.8 6.5
High (5–10) 42.3 34.6 43.6 37.7
Cognitive skills, %
Mildly
impaired
25.4 26.2 26.1 26.5
Moderately to
severely
impaired
44.4 34.2 39.6 29.4
ADL score
(0–16),
median
(Q1, Q3)§
9 (6, 12) 9 (6, 11) 10 (7, 11) 9 (7, 11)
ACE indicates angiotensin-converting enzyme; ADLs, activities of daily living; ARB,
angiotensin-receptor blocker; ATRIA, Anticoagulation and Risk Factors in Atrial
Fibrillation; NSAID, non-steroidal anti-inﬂammatory drugs; SSRI, selective serotonin
reuptake inhibitor.
*Any Part D claim during the 12-month period.
†Resident characteristics exclude residents with missing values for fall history, heart
failure, hypertension, diabetes mellitus, and stroke (n≤10 for all characteristics with
missing values in 2011 and 2016).
‡Percentages may not total 100% because of rounding.
§Higher scores indicate greater limitation in ADLs.
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Anticoagulant Use
The proportion of residents with AF treated with oral
anticoagulants was 42.4% as of July 1, 2011, at which time
the majority of treated residents were using warfarin.
Anticoagulant use remained stable through the close of
2013, at which time 42.8% of residents were treated, 35.2%
with warfarin and 7.7% with DOACs (Figure 1). Beginning in
the ﬁrst half of 2014 the prevalence of anticoagulant use
increased during each half-year through the end of the study
(December 31, 2016), at which time 47.8% of residents were
treated (P value for 2011–2016 trend <0.001). This period
(2014–2016) of increasing anticoagulant use coincided with a
decline in warfarin use and a rise in DOAC use such that by
the end of 2016, the prevalence of warfarin use (24.7%) was
nearly equal to DOAC use (23.1%).
Table 2. Characteristics of Residents Using DOACs or
Warfarin, by Time Point
December 31, 2011 December 31, 2016
Warfarin
(n=13 375)
DOAC
(n=986)
Warfarin
(n=9320)
DOAC
(n=8734)
Demographics
Age in y,
median
(Q1, Q3)
84 (78, 89) 83 (77, 88) 84 (77, 89) 83 (76, 88)
Women, % 71.1 71.6 64.6 67.3
Hospital admissions in prior year, %
Number of hospitalizations, %
2 to 3 38.2 41.0 36.8 39.1
4+ 13.9 15.7 12.5 13.8
Ischemic
stroke
7.1 10.0 5.9 8.9
Extracranial
bleed
5.0 6.5 5.0 4.0
Intracranial
hemorrhage
0.4 Sup. 0.5 0.5
Medications
Unique
medications,
median
(Q1, Q3)
19 (14, 24) 20 (15, 26) 18 (14, 23) 19 (14, 24)
Less than
standard
anticoagulant
dose, %
NA 36.0 NA 50.0
Select medications, %*
NSAID 15.6 17.9 15.1 18.7
Antiplatelet 9.2 13.8 7.5 9.7
Statin 50.7 54.0 60.2 61.1
SSRI 55.5 62.0 51.0 53.1
ACE inhibitor
or ARB
53.7 57.6 48.8 51.6
Select comorbidities, %†
Diabetes
mellitus
41.0 41.3 41.8 41.9
Heart failure 49.0 45.0 50.3 45.7
Hypertension 84.2 85.5 87.4 88.1
Coronary artery
disease
31.2 30.8 30.0 28.5
Anemia 32.4 32.5 33.9 32.5
Fall since
nursing home
admission/last
assessment
18.6 20.5 17.6 18.6
Stroke 24.2 26.8 15.7 16.7
Continued
Table 2. Continued
December 31, 2011 December 31, 2016
Warfarin
(n=13 375)
DOAC
(n=986)
Warfarin
(n=9320)
DOAC
(n=8734)
CHA2DS2-Vasc Risk Score, %
2 to 3 11.2 12.6 12.7 13.9
4 22.6 19.5 23.8 24.8
5 27.3 27.0 30.2 29.9
6 21.7 22.4 20.9 19.7
7+ 17.3 18.6 12.4 12.5
ATRIA Bleeding Risk Score, %
Low (0–3) 60.6 62.6 54.1 57.6
Intermediate
(4)
4.6 5.4 6.3 6.6
High (5–10) 34.8 32.0 39.6 35.8
Cognitive skills, %
Mildly
impaired
26.0 28.3 25.9 27.1
Moderately to
severely
impaired
34.3 33.7 28.7 30.1
ADL score
(0–16),
median
(Q1, Q3)‡
9 (6, 11) 9 (6, 11) 9 (7, 11) 9 (7, 11)
ACE indicates angiotensin-converting enzyme; ADLs, activities of daily living; ARB,
angiotensin-receptor blocker; ATRIA, Anticoagulation and Risk Factors in Atrial
Fibrillation; DOAC, direct-acting oral anticoagulant; NSAID, non-steroidal anti-
inﬂammatory drugs; SSRI, selective serotonin reuptake inhibitor; Sup., suppressed.
*Any Part D claim during the 12-month period.
†Resident characteristics exclude residents with missing values for fall history, heart
failure, hypertension, diabetes mellitus, and stroke (n≤10 for all characteristics with
missing values in 2011 and 2016).
‡Higher scores indicate greater limitation in ADLs.
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Dabigatran use increased during the early study period and
peaked in the ﬁrst half of 2012 before stabilizing in the range
of 2.2% to 3.1% through 2016 (Table 3). In contrast, the
prevalence of rivaroxaban and apixaban use continued to rise
through the end of the study. Over the 5 full years (2012–
2016) after market entry, rivaroxaban use increased from
0.4% to 8.3%. During the 4 full years after market entry
(2013–2016), apixaban use grew from 0.1% to 12.6%. In
contrast, edoxaban use remained rare after its approval in
2015.
As of the second half of 2016, 48.3% of white residents,
46.5% of black residents, 42.3% of Hispanic residents, and
36.7% of Asian/Paciﬁc Islander residents were treated with oral
anticoagulants (Table S2). No sex-based differences in antico-
agulant use were observed. In 2011, 36% of residents with
moderate-to-severe cognitive impairment were treated with
oral anticoagulants and 46.4% of cognitively intact or mildly
impaired residents were treated (Table 4); the percentages
treated in 2016 were 40.4% and 51.7%, respectively. The
change in the prevalence of oral anticoagulant use between
Figure 1. Percentage of US nursing home residents with atrial ﬁbrillation treated with warfarin and direct-acting oral anticoagulants, 2011 to
2016 by half year. DOAC indicates direct-acting oral anticoagulants; H, half.
Table 3. Percentage of Treated Residents by Anticoagulant Class and Medication
H1-2011 H2-2011 H1-2012 H2-2012 H1-2013 H2-2013 H1-2014 H2-2014 H1-2015 H2-2015 H1-2016 H2-2016
n, total 17 895 33 959 33 493 33 956 35 709 37 118 36 183 36 379 36 807 37 644 37 474 37 787
Treated, %* 42.4 42.3 43.1 42.8 42.7 42.8 43.7 44.3 44.8 45.5 47.0 47.8
Warf., % 40.5 39.4 39.4 38.4 37.0 35.2 33.6 31.8 30.6 29.0 27.3 24.7
DOAC, % 1.9 2.9 3.7 4.3 5.6 7.7 10.2 12.5 14.2 16.5 19.7 23.1
Dab., %† 1.9 2.9 3.3 3.1 2.7 2.6 2.7 2.6 Sup. Sup. Sup. 2.2
Riv., % 0.0 0.0 0.4 1.2 2.9 4.6 6.2 7.1 7.1 7.3 7.8 8.3
Apix., % 0.0 0.0 0.0 0.0 0.1 0.5 1.3 2.8 4.7 7.0 9.8 12.6
Edox., %† 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Sup. Sup. Sup. 0.1
Apix. indicates apixaban; Dab., dabigatran; DOAC, direct-acting oral anticoagulant; Edox., edoxaban; H, half; Riv., rivaroxaban; Warf., warfarin.
*Treated percentage may not equal the sum of warfarin and DOAC percentages because of rounding.
†Cell values suppressed to prevent any individual cell size from being <11.
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2011 and 2016 was 5% among residents with and without
chronic renal insufﬁciency (43% to 48%); the change among
those with end-stage renal disease was 8% (39% to 47%)
(Table 5). In 2016, use of low DOAC doses was common (44%)
among residents without a diagnosis of renal impairment, while
standard DOAC doses were commonly used among those with
chronic renal insufﬁciency (47%), end-stage renal disease (40%),
and those on dialysis (31%). Among 2676 apixaban users likely
to have an indication for dosage reduction (at least 2 of the
following: weight ≤60 kg, renal impairment, age ≥80 years),
26.2% received the standard dose. Among 3122 apixaban users
who likely did not have an indication for dose reduction, 36.0%
received the low dose.
Anticoagulant Switching and Discontinuation
The proportion of nursing home residents with AF discontin-
uing oral anticoagulants was in the range of 8.6% to 10.1% for
each half-year of the study period (Figure 1). Among treated
residents, the fraction switching from a DOAC to warfarin
remained in a narrow range (1.8%–2.4%) from the second half
of 2011 through the end of 2016 (Figure 2). Switchers from
warfarin to a DOAC comprised 2.4% of treated residents in the
ﬁrst half of 2011 and 7.8% of treated residents in the second
half of 2016. Among residents that switched between
anticoagulant classes, the percentage of switchers that
switched back to their original anticoagulant class ranged
from 13% to 21% of all switchers during 2011 and 2012, and
from 8% to 11% of all switchers during 2013 to 2016 (1% of
the total treated population).
Discussion
The proportion of US nursing home residents with AF using
oral anticoagulants was stable during the initial 3-year period
following the market release of the DOACs in the United
States, but then steadily increased from 2014 to 2016.
Underlying this overall trend, the pace of gradual decline in
warfarin use mirrored uptake in DOAC use during 2011 to
2013, with DOAC uptake consistently outpacing declines in
warfarin use beginning in 2014. Utilization growth peaked for
dabigatran in 2012 and slowed for rivaroxaban in 2015.
Continued increases in DOAC use and anticoagulation overall
were fueled by the rapid uptake of apixaban, which began
1 year after its market entrance (2014) and was sustained
through the end of 2016. By the end of 2016, approximately
Table 4. Percentage of Nursing Home Residents With Atrial
Fibrillation Treated With Oral Anticoagulants by Cognitive
Status and Functioning in ADLs
December 31, 2011 December 31, 2016
Cognitively
Intact or
Mild
Impairment
Moderate or
Severe
Cognitive
Impairment
Cognitively
Intact or
Mild
Impairment
Moderate or
Severe
Cognitive
Impairment
n 20 338 13 621 24 660 13 127
Treated, % 46.4 36.1 51.7 40.4
ADL Score
0 to 4, n*
4275 772 4076 677
Treated, % 46.9 33.0 51.7 40.9
ADL Score
5 to 8, n*
6401 2470 7714 2349
Treated, % 45.5 35.7 51.5 43.1
ADL Score
9 to 12, n*
8195 5953 11 501 6850
Treated, % 47.1 37.0 52.3 40.3
ADL Score
13 to 16, n*
1467 4426 1369 3251
Treated, % 45.5 35.7 48.1 38.7
ADLs indicates activities of daily living.
*Higher scores indicate greater limitation in ADLs.
Table 5. Anticoagulant Use by Renal Function Among
Nursing Home Residents With Atrial Fibrillation
No
Diagnosis
of Renal
Insufﬁciency
Chronic
Renal
Insufﬁciency*
End-Stage
Renal
Disease†
On
Dialysis‡
December 31, 2016
n 18 606 10 956 7014 1211
Treated, % 47.8 48.5 47.1 44.2
Warfarin, % 24.0 24.2 25.8 33.1
Low-dose
DOAC, %
10.5 12.9 12.8 7.7
Standard-dose
DOAC, %
13.4 11.4 8.4 3.4
December 31, 2011
n 19 319 9116 4713 811
Treated, % 43.1 42.8 38.5 39.7
Warfarin, % 40.0 39.8 36.1 39.7
Low-dose
DOAC, %
0.8 1.4 1.3 0.0
Standard-dose
DOAC, %
2.2 1.6 1.1 0.0
DOAC indicates direct-acting oral anticoagulant.
*Identiﬁed from in-patient diagnoses. Corresponds to an estimated glomerular ﬁltration
rate <60 mL/min. Residents with evidence of more severe disease (end-stage renal
disease or on dialysis) were assigned to the more severe category.
†Identiﬁed from the most recent MDS 3.0 assessment (item I1500: end-stage renal
disease). Residents with evidence of more severe disease (on dialysis) were assigned to
the more severe category.
‡Identiﬁed from the most recent MDS 3.0 assessment (item O0100J2) which indicates
whether the resident has received dialysis within the past 14 days while a resident of the
nursing facility.
DOI: 10.1161/JAHA.119.012023 Journal of the American Heart Association 7
Anticoagulant Use in US Nursing Homes Alcusky et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on June 26, 2019
equal fractions of residents were treated with DOACs as were
treated with warfarin.
Before DOAC availability, low use of oral anticoagulants
among high-risk older adults with AF was reported in the United
States and internationally.6,30,31 In 2 large US community-
based AF cohorts (median CHA2DS2-Vasc: 5), >40% of patients
hospitalized for ischemic stroke were discharged without an
anticoagulant.4 Estimates of anticoagulant use among US
nursing home residents with AF in the 1990s and early 2000s
suggested approximately two thirds of residents were not
treated with warfarin.9,32 At that time, reports of high rates of
adverse events and labile international normalized ratios for
nursing home residents11,33 were accompanied by physician
uncertainty about the relative beneﬁts and risks of warfarin in
the long-term care setting.5 This uncertainty about the net
beneﬁt of treatment continues to affect anticoagulant pre-
scribing decisions for high-risk older adults.4
Low use of anticoagulation was widespread despite
evidence supporting clinical beneﬁt. A meta-analysis of
clinical trials comparing warfarin with control reported a
64% risk reduction for stroke and comparable risk for major
extracranial hemorrhage in patients with AF.34 Similar ﬁndings
were reported for warfarin versus aspirin among older adults
aged >75 years.7 Prominent reasons clinicians refrain from
anticoagulation among high-risk older adults post-stroke
include perceived fall risk, poor prognosis, and a history of
bleeding.4,5 Considering a history of falls is common among
nursing home residents, coupled with a high burden of
cognitive impairment14 and short-life expectancy,15 it is
reasonable to expect a lower prevalence of anticoagulation
compared with community-dwelling populations. Interestingly,
although the prevalence of bleeding risk factors was direc-
tionally consistent with greater provider caution in treating
patients with higher bleeding risk, more than half of the
untreated population had low bleeding risk (ATRIA <4) and
more than three quarters did not have a recent history of falls.
This suggests a role for other factors beyond these commonly
reported reasons for not prescribing oral anticoagulants. In
this respect, our ﬁndings were similar to earlier studies in the
nursing home setting which reported lower likelihood of
preventative treatment for residents with cognitive impair-
ment in addition to atrial ﬁbrillation32 or prior myocardial
infarction.35 However, existing functional limitations did not
appear to deter anticoagulant use in our study population, as
treated fractions were generally consistent across levels of
functional limitation.
Even in the presence of bleeding risk factors, cognitive
impairment, and/or functional limitations, clinicians should
maintain a focus on the overall risk-beneﬁt proﬁle, while
incorporating patient and family input. Patients often place
Figure 2. Percentage of treated residents that switched between warfarin and direct-acting oral anticoagulants,* 2011 to 2016 by half year.
*Residents that made multiple switches were grouped according to their most recent switch. DOAC indicates direct-acting oral anticoagulants;
H, half.
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greater weight on the prevention of stroke than the risk of
bleeding,36 which may reﬂect recognition of stroke’s long-
term consequences for functioning and cognition.37,38 How-
ever, patient aversion to bleeding risk as well as the need for
additional blood testing and clinical evaluation, even with
DOACs, may also contribute to lower treatment rates than
would be expected if guidelines were strictly followed. Beyond
the decision to treat, the selection of dosage may also be
affected by resident factors associated with perceived bleeding
and stroke risk, potentially leading to dosing that is inconsistent
with product labeling. In a large US cohort of privately insured
andMedicare Advantage enrollees with atrial ﬁbrillation, 43% of
DOAC users received standard doses in the presence of a renal
indication for dose reduction while 13% received low doses
despite no renal indication.39 In the nursing home population,
we estimated 44% of DOAC users without renal impairment
(renal insufﬁciency, end-stage disease, or on dialysis) received
low dosages and 44% with renal impairment received standard
dosages. In the community dwelling population, overdosingwas
associated with a >2-fold increased risk of bleeding and
comparable stroke risk, while under dosingwas associated with
a >4-fold higher stroke risk among apixaban (but not rivarox-
aban or dabigatran) users.39
After DOACs became available, changes in anticoagulant
utilization among US nursing home residents were delayed
and smaller in magnitude compared with changes in the
broader community-dwelling population. The prevalence of
anticoagulant use among nursing home residents with AF had
already increased from 30% in 200410 to 43% at the start of
our study (2011). In the early period of DOAC availability, the
percentage of residents anticoagulated remained steady
before increasing to 48% during 2014 to 2016. This contrasts
with the ambulatory care population, where the percentage of
ofﬁce-based visits for AF with anticoagulant use increased
from 52% in 2009 to 67% by the end of 2014.12 The rate of
diffusion of DOACs in the community was also faster than in
the nursing home, as the number of ofﬁce visits for AF with
DOAC use equaled the number of visits with warfarin use by
the close of 2013.12 The proportion of nursing home residents
using DOACs did not approach the proportion using warfarin
until the end of 2016. However, increases in anticoagulant
and DOAC use continued through the end of our study,
suggesting these trends may have continued into 2017. The
uptake of DOACs among Medicare Supplemental enrollees in
the community was slower than the broader community-
dwelling population and more closely resembled uptake
among nursing home residents.40
Clinical trial evidence comparing DOACs to warfarin speciﬁc
to older adults is limited. Meta-analysis of available trial data has
suggested the DOACs have similar or improved efﬁcacy and
comparable or lower risk of major bleeding (except for dabiga-
tran) compared with warfarin in adults aged ≥75 years.41,42
Although time in therapeutic range was below target levels in the
DOAC trials (55%–65%),42 similar to studies of real-world
populations,43 inferences on comparative effectiveness among
older adults maintained within warfarin’s therapeutic range
require additional evidence. In the absence of deﬁnitive evidence
in older frail populations, and in light of highly similar resident
characteristics for DOAC and warfarin users in 2016, the
increase in anticoagulant use during 2014–2016may have been
driven by several factors. American College of Cardiology/
American Heart Association guidelines for AF management
published in 2014 listed warfarin and DOACs as class one
options for non-valvular AF.44 Lack of monitoring requirements,
fewer drug and dietary interactions, and less frequent need for
dose adjustments may have contributed to subgroups of
patients receiving treatment with DOACs that historically would
not have received warfarin. Furthermore, superiority in safety
and effectiveness of apixaban versus warfarin in the ARISTOTLE
(Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation) trial45 may have tipped the balance of
perceived risks and beneﬁts in favor of treatment for certain
residents, a possibility supported by the timing andmagnitude of
increases in apixaban use.
Limitations
In this ﬁrst national study of anticoagulant use in nursing
homes since 2004, we used daily tracking of exposure and
repeated point prevalence measurements to understand the
evolution of anticoagulant use while accounting for switching
and discontinuation. Limitations stem primarily from the use
of diagnostic and medication utilization information derived
observational data sources. Detailed clinical data on the type
of AF, AF disease history, and renal functioning were not
available. Use of over-the-counter medications such as aspirin
was not observed unless there was a Part D claim.
Anticoagulant exposure was estimated based on medication
ﬁll patterns and actual use may have differed, although non-
adherence is less of a concern because of the nature of
medication administration in nursing homes. Finally, this was
a population-based study which used a repeated cross-
sectional design to describe patterns of real-world medication
use over time among US nursing home residents with AF.
Although we describe resident characteristics in 2011 and
2016, the contributions of within-resident correlation and
changes in the characteristics of the US nursing home
population over time to changes in anticoagulant utilization
patterns were not evaluated statistically in the present study.
Conclusions
Even after a marked increase in anticoagulant use between
2004 and 2016, more than half of nursing home residents
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with AF remain untreated. The large majority of residents with
AF are at high risk for stroke, evidenced by 85% of residents
with a CHA2DS2-Vasc score of ≥4. Recent estimates (2013–
2016) of anticoagulant use in the community indicate a large
majority (75%) of new-users are initiating DOACs, including
older adults.13 With recent availability of DOAC reversal
agents46 and emerging observational evidence reinforcing trial
ﬁndings in real-world populations,47,48 including the frail,49 it is
likely the gradual increase in anticoagulation of nursing home
residents and ongoing shift from warfarin to DOACs will
continue. The early plateau in dabigatran use suggests any
further increase in DOAC use among nursing home residents is
likely to be driven by the factor Xa inhibitors apixaban, and to a
lesser extent, rivaroxaban. Comparative effectiveness research
speciﬁc to this medically complex older adult population is
warranted to determine the clinical implications of these shifts
in anticoagulant prescribing.
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Table S1. ICD-9 and ICD-10 Code Based Definitions Applied to Medicare Part A Claims to Identify 
Specific Conditions.
Clinical Condition ICD-9 CM Codes ICD-10 CM Codesa
Atrial 
fibrillation/flutter1,*
42731, 42732 I480, I481, I482, I483, I484, I4891, I4892 
Ischemic stroke2 43301, 43311, 43321, 43331, 43381, 
43391, 43401, 43411, 43491, 436 
I6302, I6312, I6322, I63239, I63232, 
I63231, I63139, I63132, I63131, I63039, 
I63032, I63031, I63011, I63012, I63019, 
I63111, I63112, I63119, I63211, I63212, 
I63219, I6359, I6319, I6309, I6329, 
I6320, I6310, I6300, I6330, I63311, 
I63312, I63319, I63321, I63322, I63329, 
I63331, I63332, I63339, I63341, I63342, 
I63349, I6339, I636, I6349, I63449, 
I63442, I63441, I63439, I69432, I69431, 
I63429, I63422, I63421, I63419, I63412, 
I63411, I63430, I6350, I63511, I63512, 
I63519, I63521, I63529, I63531, I63532, 
I63539, I63541, I63542, I63549, I6359, 
I638, I639, I6789 
Intracranial 
hemorrhage3
430, 431, 4320, 4321, 4329 I609, I608, I607, I606, I6052, I6051, 
I6050, I604, I6032, I6031, I6030, I6022, 
I6021, I6020, I6012, I6011, I6010, I6002, 
I6001, I6000, I610, I611, I612, I613, I614, 
I615, I616, I618, I619, I621, I6200, I6201, 
I6202, I6203, I629 
Extracranial 
bleeding3
In primary position alone: 
5310, 5312, 5314, 5316, 5320, 5322, 
5324, 5326, 5330, 5332, 5334, 5336, 
5340, 5342, 5344, 5346, 53501, 53511, 
53521, 53531, 53541, 53551, 53561, 
53783, 4560, 45620, 5307, 53082, 
5780, 4552, 4555, 4558, 56202, 56203, 
56212, 56213, 56881, 5693, 56985, 
5781, 5789, 59381, 5997, 6238, 6262, 
6266, 4230, 4590, 56881, 7191, 7847, 
7848, 7863 
In primary position, with above code in 
secondary position: 
5311, 5313, 5315, 5317, 5319, 5321, 
5323, 5325, 5327, 5329, 5331, 5333, 
5335, 5337, 5339, 5341, 5343, 5345, 
5347, 5349, 53500, 53510, 53520, 
53530, 53540, 53550, 53560, 455, 
56200, 56201, 56210, 56211, 5301, 
2800, 2851, 2859, 79092 
In primary position alone: 
K252, K254, K256, K260, K262, K264, 
K266, K270, K272, K274, K276, K280, 
K282, K284, K286, K2901, K2931, 
K2941, K2951, K2961, K2921, K2971, 
K2981, K2991, K31811, I8501, I8511, 
K226, K228, K920, K648, K643, K642, 
K641 K640, K5711, K5751, K5753, 
K5741, K5713, K5701, K5791, K5731, 
K5793, K5781, K5733, K5721, K661, 
K625, K5521, K921, K922, N280, R310, 
R311, R312, R319, N898, N920, N921, 
I312, R58, M2500, M25011, M25012, 
M25019, M25021, M25022, M25029, 
M25031, M25032, M25039, M25041, 
M25042, M25049, M25051, M25052, 
M25059, M25061, M25062, M25069, 
M25071, M25072, M25073, M25074, 
M25075, M25076, M2508, R040, R041, 
R042, R0481, R0489, R049 
In primary position, with above code in 
secondary position: 
K251, K253, K255, K257, K259, K261, 
K263, K265, K267, K269, K271, K273, 
K275, K277, K279, K281, K283, K285, 
K287, K289, K2900, K2930, K2960, 
K2920, K2930, K2970, K2980, K640, 
K641, K642, K643, K644, K645, K648, 
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K649, K5750, K5710, K5752, K5740, 
K5712, K5700, K5730, K5790, K5792, 
K5780, K5732, K5720, K210, K209, 
K208, K200, D800, D62, D649, R791 
Chronic renal 
insufficiency4
582, 583, 585, 586, 587 M3218, M3214, M3504, N050, N051, 
N052, N053, N054, N055, N056, N057, 
N058, N059, N060, N061, N062, N063, 
N064, N065, N066, N067, N068, N069, 
N070, N071, N072, N073, N074, N075, 
N076, N077, N078, N079, N08, N140, 
N142, N144, N150, N158, N159, N171, 
N16, N170, N172, N178, N179, N181, 
N182, N183, N184, N185, N186, N189, 
N19, N261, N269 
*ICD-9 CM code based algorithms were converted to ICD-10 CM codes using the 2016 General Equivalence
Mappings available from the Centers for Medicare and Medicaid Services at
https://www.cms.gov/Medicare/Coding/ICD10/2016-ICD-10-CM-and-GEMs.html
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Table S2. Percentage of Residents Treated with Oral Anticoagulants by Race/Ethnicity.
Time Period Overall White Black Hispanic API Other/Unknown 
First half 2011 
n 17,895 15,404 1,421 688 257 125 
Treated, % 42.4 42.6 41.5 42.4 32.7 43.5 
Second half 2011 
n 33,959 29,268 2,623 1,316 530 222 
Treated, % 42.3 42.8 40.3 39.7 31.7 39.9 
First half 2012 
n 33,493 28,766 2,690 1,297 507 233 
Treated, % 43.1 43.4 43.1 40.2 35.7 44.6 
Second half 2012 
n 33,956 29,062 2,724 1,357 554 269 
Treated, % 42.8 43.2 42.0 39.9 32.9 37.8 
First half 2013* 
n 35,709 30,532 2,836 1,371 571 283 
Treated, % 42.7 43.2 40.6 40.8 31.4 40.7 
Second half 2013* 
n 37,118 31,524 2,926 1,454 590 300 
Treated, % 42.8 43.5 40.9 39.1 29.3 39.0 
First half 2014 
n 36,183 30,808 3,041 1,425 587 322 
Treated, % 43.7 44.4 42.3 39.4 30.7 41.3 
Second half 2014 
n 36,379 31,013 3,035 1,407 585 339 
Treated, % 44.3 44.8 43.0 40.9 32.3 41.3 
First half 2015 
n 36,807 31,490 3,071 1,354 560 332 
Treated, % 44.8 45.3 43.8 42.5 31.6 43.7 
Second half 2015 
n 37,644 32,222 3,068 1,410 595 349 
Treated, % 45.5 46.0 43.8 43.0 33.8 43.8 
First half 2016 
n 37,474 31,801 3,228 1,489 601 355 
Treated, % 47.0 47.4 47.7 42.9 37.6 43.7 
Second half 2016 
n 37,787 31,985 3,255 1,578 608 361 
Treated, % 47.8 48.3 46.5 42.3 36.7 54.3 
*Race/ethnicity missing for 116 residents in the first half of 2013 and 324 residents in the second half of 2013 
Abbreviations: Asian or Pacific Islander (API).
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